Amsterdam UMC proudly presents new spin-off Kling BioTherapeutics

Kling BioTherapeutics is a newly-formed Amsterdam UMC spin-off that is discovering and developing innovative antibody and antibody-derived drugs to treat cancer and infectious disease patients. With its lead program preparing to enter human clinical trials, Kling is well positioned to become an immuno-oncology biotech leader with a novel discovery platform and a robust pipeline of first in class oncology antibodies. Amsterdam UMC has partnered with U.S.-based venture capital firm Time BioVentures to build Kling, and is excited by the company’s rapid progress in attracting a world-class management team of seasoned drug development executives with impressive track records bringing breakthrough products to patients. The company’s offices and labs are located on Amsterdam UMC’s Meibergdreef campus.